Oncternal Therapeutics Inc Stock price
Is Oncternal Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?
As a Free StocksGuide user, you can view scores for all 9,127 stocks worldwide.
Key metrics
Oncternal Therapeutics Inc Stock Analysis
Analyst Opinions
6 Analysts have issued a Oncternal Therapeutics Inc forecast:
Analyst Opinions
6 Analysts have issued a Oncternal Therapeutics Inc forecast:
Don't miss a Thing! We will send you all news about Oncternal Therapeutics Inc directly to your mailbox free of charge.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Company Profile
Oncternal Therapeutics, Inc. is a clinical-stage oncology company, which develops a diverse pipeline of treatments for cancers with critically unmet medical need. Its focuses on drug development of untapped biological pathways implicated in cancer progression. The company was founded by David F. Hale and James B. Breitmeyer in 1997 and is headquartered in San Diego, CA.
| Head office | United States |
| CEO | Mr. Breitmeyer |
| Employees | 29 |
| Founded | 1997 |
| Website | www.oncternal.com |


